Ask AI
ProCE Banner Activity

European Perspective on Today’s Approaches to Optimize the Care of Patients With Mantle Cell Lymphoma

Clinical Thought

In this commentary, an expert addresses the expanding role of BTK inhibitors and chemotherapy-free regimens in the management of patients with MCL and the importance of proactively managing treatment-related adverse events to extend duration on treatment and improve clinical outcomes and quality of life.

Released: February 02, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for global hematology/oncology physician specialists and other healthcare professionals providing care for patients with mantle cell lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan BTK inhibitor-based combination strategies for patients with treatment-naïve MCL, considering new indications, expert recommendations, and available efficacy and safety evidence

  • Select chemotherapy-free treatment strategies for appropriate patients with MCL

  • Manage treatment-related adverse events associated with targeted therapies alone or in combination to extend duration on treatment and improve clinical outcomes. 

Disclosure

Primary Author

Mats Jerkeman, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Kite/Gilead, Lilly, Roche.